“Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL Evaluation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.”

…is the name on a recent study published in European Journal of Heart Failure

The bottomline is that IF you use NGAL as a marker along with the standart BNP test, you will be able to determine with much higher certainty, which patients will be likely to endure a re-admission.

It holds unknown potential, but we think that it will add to the future value of having a widely used NGAL test.

About Karl M. Bidstrup

Tidligere ejer af Medicoinvestor.com Strategien har gennem mange år været at profitere på etablerede aktier, og brænde det hele af på Bioporto... Sad but true. Kontakt mig på medicoinvestor(A)gmail.com hvis du har en million du ikke ved hvor du skal gemme, så skal jeg nok holde den for dig. 🙂

Tagged with:

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.